Adaptive Biotechnologies vs Iovance Biotherapeutics
Adaptive Biotechnologies and Iovance Biotherapeutics are similar in size: $277m and $264m of revenue in their latest fiscal years. Iovance Biotherapeutics grew faster (60.6% against 54.8%). Adaptive Biotechnologies kept more of each dollar of sales as profit: a net margin of -21.5% against -148.4%.
| Latest fiscal year | Adaptive BiotechnologiesADPT, 2025 | Iovance BiotherapeuticsIOVA, 2025 |
|---|---|---|
| Revenue | $277m | $264m |
| Revenue growth | 54.8% | 60.6% |
| Net income | −$59.5m | −$391m |
| Operating margin | -20.6% | — |
| Net margin | -21.5% | -148.4% |
| Return on equity | -28.2% | -55.5% |
| Free cash flow | −$48.9m | −$336m |
| Cash | $70.5m | $163m |
| Total debt | $131m | — |
| Debt to equity | 60.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 624 | 975 |
| Market value | $4.10bn | $3.95bn |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 0 buys, 168 sales | 0 buys, 0 sales |